Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection. – PubMed

Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection. - PubMed

Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection. - PubMed
Figure 1: HSV-2 titers in the vaginal tract after infection with the attenuated viruses HSV-2(333)/gD-βgal or HSV-2(333)/Δ7-15-βgal are only minimally affected by engagement of HVEM. When you draw blood levels for Antibody Titers, it just means that your body has been in contact with that germ(HSV), and it has responded the correct way, and made killer cells against it. dl5-29-41L has a decreased ability to inhibit host cell protein synthesis and a reduced cytopathic effect on cultured cells. Vero cells in EX-CELL Vero were infected with Herpes Simplex Virus-Type 2 (HSV-2) and produced on average 106.0 TCID50/mL at a multiplicity of infection (MOI) of 0.01. The FHV-1-infected cultures were evaluated for viral-induced cytopathic effects, and viral titers were determined in samples of culture supernatant. The protocol with three intramuscular immunizations combining sgG-2 with cytosine-phosphate-guanine dinucleotide (CpG) motifs and alum induced almost complete protection from genital and systemic disease after intra-vaginal challenge with HSV-2. Robust immunoglobulin G (IgG) antibody titers were detected with no neutralization activity.

That is what has happened in your case. sgG-2 + adjuvant intra-muscularly immunized mice showed a significant reduction of infectious HSV-2 and increased IFN-γ levels in vaginal washes. Additionally, the liquid formulation of EX-CELL Vero is formulated without L-glutamine, which avoids problems associated with L-glutamine degradation, therefore improving product shelf life. We show that a sgG-2 based vaccine is highly effective and can be considered as a novel candidate in the development of a prophylactic vaccine against HSV-2 infection.

You may also like